Latest Updates
-
Purported Video of Muslim Mob Lynching & Hanging Hindu Youth In Bangladesh Shocks Internet -
A Hotel on Wheels: Bihar Rolls Out Its First Luxury Caravan Buses -
Bharti Singh-Haarsh Limbachiyaa Welcome Second Child, Gender: Couple Welcome Their Second Baby, Duo Overjoyed - Report | Bharti Singh Gives Birth To Second Baby Boy | Gender Of Bharti Singh Haarsh Limbachiyaa Second Baby -
Bharti Singh Welcomes Second Son: Joyous News for the Comedian and Her Family -
Gold & Silver Rates Today in India: 22K, 24K, 18K & MCX Prices Fall After Continuous Rally; Check Latest Gold Rates in Chennai, Mumbai, Bangalore, Hyderabad, Ahmedabad & Other Cities on 19 December -
Nick Jonas Dancing to Dhurandhar’s “Shararat” Song Goes Viral -
From Consciousness To Cosmos: Understanding Reality Through The Vedic Lens -
The Sunscreen Confusion: Expert Explains How to Choose What Actually Works in Indian Weather -
On Goa Liberation Day 2025, A Look At How Freedom Shaped Goa Into A Celebrity-Favourite Retreat -
Daily Horoscope, Dec 19, 2025: Libra to Pisces; Astrological Prediction for all Zodiac Signs
New Drug For Breast Cancer Treatment
A new drug, called Pertuzumab, related to the controversial drug Herceptin, may pave the way for new treatment of breast cancer.
Pertuzumab works in the same way as Herceptin by targeting the HER-2 gene found in 20 per cent of breast cancer patients.
However, the difference between the two lies in the fact that Herceptin blocks a molecular "switch" that promotes cancer growth, while Pertuzumab completely eradicates the possibility of having the switch at all.
This is the first drug to put into effect this sort of modus operandi. And when the scientists used the results of a “phase two" trial of this drug for treating advanced cancer patients, it showed promising results.
It was found that nearly one fourth of the 66 patients reported disappearance or shrinkage of their tumours. Also, the cancer completely vanished in 8 per cent of cases. In fact, a good 25 per cent of patients reported stabilisation of their cancers for at least six months.
It was found that all the patients in the study were at a stage in their illness where their disease was progressing despite treatment with Herceptin and Pertuzumab was administered as an additional therapy.
The
scientists
conducted
their
study
at
Mount
Vernon
Hospital,
London,
and
announced
it
at
the
American
Society
of
Clinical
Oncology
in
Chicago.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications











